Parabilis Medicines is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies that target previously undruggable proteins. The company has pioneered a new class of stabilized, cell-penetrant alpha-helical peptides known as Helicons™, which are designed to modulate intracellular proteins that traditional drug modalities cannot reach. Parabilis is advancing a pipeline of first-in-class therapies for both rare and common cancers, including its lead candidate FOG-001, aimed at inhibiting β-catenin interactions in various tumors. Committed to precision medicine, Parabilis fosters a collaborative and growth-minded environment, prioritizing patient outcomes and driving scientific innovation to improve treatment options.